Alnylam Pharmaceuticals, Inc. (0HD2.L) LSE

286.14

-14.8607(-4.94%)

Updated at June 02 06:39PM

Currency In USD

Key Executives

Name	Title	Pay	Year Born
Yvonne L. Greenstreet	Chief Executive Officer & Director	4.99M	1963
Phillip A. Sharp	Co-Founder, Member of the Scientific Advisory Board	52,930	1945
Bryan Andrew Supran	Chief Legal Officer	845,920	1970
Kevin Joseph Fitzgerald	Executive Vice President, Chief Scientific Officer and Head of Early Research & Early Development	1.23M	1968
Tolga Tanguler	Executive Vice President & Chief Commercial Officer	1.5M	1973
Jeffrey V. Poulton	Chief Financial Officer & Executive Vice President	1.7M	1968
Pushkal Garg	Executive VP & Chief Research & Development Officer	1.86M	1968
Muthiah Manoharan	Senior Vice President of Innovation Chemistry & Distinguished Scientist and Member of Scientific Advisory Board	0	1953
Piyush Sharma	Chief Ethics & Compliance Officer	0	N/A
Timothy J. Maines	Chief Technical Operations & Quality Officer	0	N/A
Christine Regan Akinc	Chief Corporate Communications Officer	0	1982
Melissa McLaughlin	Chief Human Resources Officer	0	N/A

Name

Title

Pay

Year Born

Yvonne L. Greenstreet

Chief Executive Officer & Director

4.99M

1963

Phillip A. Sharp

Co-Founder, Member of the Scientific Advisory Board

52,930

1945

Bryan Andrew Supran

Chief Legal Officer

845,920

1970

Kevin Joseph Fitzgerald

Executive Vice President, Chief Scientific Officer and Head of Early Research & Early Development

1.23M

1968

Tolga Tanguler

Executive Vice President & Chief Commercial Officer

1.5M

1973

Jeffrey V. Poulton

Chief Financial Officer & Executive Vice President

1.7M

1968

Pushkal Garg

Executive VP & Chief Research & Development Officer

1.86M

1968

Muthiah Manoharan

Senior Vice President of Innovation Chemistry & Distinguished Scientist and Member of Scientific Advisory Board

1953

Piyush Sharma

Chief Ethics & Compliance Officer

N/A

Timothy J. Maines

Chief Technical Operations & Quality Officer

N/A

Christine Regan Akinc

Chief Corporate Communications Officer

1982

Melissa McLaughlin

Chief Human Resources Officer

N/A

Description

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.